New Funds Will be Used to Develop Commercial Offering
Cambridge, 7 September 2015 … Repositive, a software company developing novel tools to improve access to genomic research data, has announced it has started a Series A fundraising, as it accelerates the commercialisation of its genomic data platform.
The new funds will be used to develop Repositive’s commercial offering, particularly to enterprise users in genomics R&D, as well as expand and improve the current Repositive platform. The company is raising funds to reach milestones for development and sales and the company is in discussions with both current and new investors.
Fiona Nielsen, CEO of Repositive, said: “This funding will be crucial to develop the commercial offering from Repositive. We have had strong interest in the early version of the Repositive platform and with the increased funding we can expand this to a full enterprise offering.”
Since the establishment of Repositive in August 2014, the company has made significant progress in developing the online Repositive platform which is due for public launch in early 2016. The Repositive platform for making data visible and accessible is currently beta testing for selected early access users from both commercial and academic organisations. The Repositive platform allows scientists to quickly and easily access data from a range of global sources, and will make it easy to initiate data collaborations with both colleagues and external collaborators.
Alongside the development of the platform, Repositive have expanded the team with a number of key hires including software development, web design, operations and support, and communications and marketing. In addition, the company now has dedicated offices in Cambridge.
Repositive has also been active in securing further commercial partnerships, and has a number of discussions currently in progress.
Help employers find you! Check out all the jobs and post your resume.
Cambridge, 7 September 2015 … Repositive, a software company developing novel tools to improve access to genomic research data, has announced it has started a Series A fundraising, as it accelerates the commercialisation of its genomic data platform.
The new funds will be used to develop Repositive’s commercial offering, particularly to enterprise users in genomics R&D, as well as expand and improve the current Repositive platform. The company is raising funds to reach milestones for development and sales and the company is in discussions with both current and new investors.
Fiona Nielsen, CEO of Repositive, said: “This funding will be crucial to develop the commercial offering from Repositive. We have had strong interest in the early version of the Repositive platform and with the increased funding we can expand this to a full enterprise offering.”
Since the establishment of Repositive in August 2014, the company has made significant progress in developing the online Repositive platform which is due for public launch in early 2016. The Repositive platform for making data visible and accessible is currently beta testing for selected early access users from both commercial and academic organisations. The Repositive platform allows scientists to quickly and easily access data from a range of global sources, and will make it easy to initiate data collaborations with both colleagues and external collaborators.
Alongside the development of the platform, Repositive have expanded the team with a number of key hires including software development, web design, operations and support, and communications and marketing. In addition, the company now has dedicated offices in Cambridge.
Repositive has also been active in securing further commercial partnerships, and has a number of discussions currently in progress.
Help employers find you! Check out all the jobs and post your resume.
